CompletedNCT05136690

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

Medication studyAges 18–55United StatesSchizophrenia

The study in practice

Understand this study

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations: Long Beach, United States · Marlton, United StatesSee all locations and recruitment
Activities: Medication described in the protocol · Placebo described in the protocol; its role is not resolved here
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: April 27, 2022

Recruitment status: Completed
Enrollment listed in the registry: 38
Sponsor: Merck Sharp & Dohme LLC
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT05136690
Official title: Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Cross-over Evaluation of Evoked Responses as Pharmacodynamic Biomarkers in Healthy Adults and Schizophrenic Patients

Completed

Long Beach · Marlton

FAQ

Who is behind this study?

The study sponsor is Merck Sharp & Dohme LLC.

Did this study involve medication?

Yes. The study involved medication, including Nicotine patch, MK-4334, Placebo patch and Placebo capsule.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.